AstraZeneca (AZN) Withdraws App for Ovarian-Cancer Treatment in Europe
- Donald Trump Sworn in as 45th U.S. President
- Wall Street ends higher as Trump becomes president
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Apple (AAPL) Sues Qualcomm (QCOM) Over Patent Royalties in Antitrust Case - Bloomberg
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
AstraZeneca (NYSE: AZN) is said to have withdrawn its application for approval of cediranib in Europe following a disagreement with regulators.
Bloomberg noted that the action won't affect development of the ovarian cancer treatment.
AstraZeneca filed an application with the European Medicines Agency in June 2015 seeking approval of cediranib for use with platinum-based chemotherapy in adults with a type of ovarian cancer that’s relapsed.
Shares of AstraZeneca are indicated lower Wednesday morning.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bristol-Myers lung cancer delay slams shares, keeps Merck in lead
- Active options: AAPL IBM ARNC FB BAC SWKS AMZN GE NFLX SGYP
- iPath S&P 500 VIX ST Futures ETN (NYSE: VXX) down 1.7%
Create E-mail Alert Related CategoriesFDA, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!